Archive for 2011

Speeding Time to Market Cost-Effectively

With the recent news of pharma’s frustration with more price controls around the world, John Avellanet, frequent Biotech Blog poster and author of Get to Market Now!, is grinning right now for having predicting a strengthening of such price controls back in 2009 and in 2010.  Here is a brief interview with John, covering price […]


Conference on Breathing Additional Life into the Life Sciences – Reaching the Next Milestone

The Journal of Commercial Biotechnology, published by the owner of BiotechBlog, is proud to serve as a media sponsor for this upcoming conference on biotechnology development. Reaching the Next Milestone Conference on Breathing Additional Life into the Life Sciences Date: Friday, November 4, 2011          Time: 7:30 AM to 3:00 PM Purpose of Conference The future for […]


New Book – Great Patents: Advanced Strategies For Innovative Growth Companies

I’ve just published a new book by David Orange. Great Patents: Advanced Strategies For Innovative Growth Companies is a compilation of expert opinions on important topics in managing and protecting a company’s intellectual property. Patents are more than just legal forms for lawyers to fill out or clubs to use in infringement lawsuits. They can […]


Drug Patent Expirations in September 2011

Drug Patent Expirations in September 2011 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration SEREVENT Glaxo Grp Ltd salmeterol xinafoate 7,225,808*PED Sep 1, 2011 ADVAIR DISKUS 500/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate 5,590,645*PED Sep 1, 2011 ADVAIR DISKUS 250/50 Glaxosmithkline fluticasone propionate; salmeterol xinafoate 6,792,945*PED Sep 1, 2011 […]


Promoting online drug safety: Using public–private partnerships to deter illicit online drug sales

Illicit online pharmacies selling counterfeit drugs in a global virtual marketplace remain a critical problem in global health. Yet they continue to operate with little regulation while growing numbers of consumers access the Internet for health inform…


Public–private partnerships in addressing counterfeit medicines: The development of the Partnership for Safe Medicines and the Partnership for Safe Medicines-India

The global drug supply chain has resulted in tremendous vulnerabilities. Despite individual country efforts, both developed and resource-poor countries have experienced tremendous challenges with ensuring safety of the drug supply. In this piece, the f…


Enforcement efforts and partnership with industry: A needed strategy addressing counterfeit drugs

Despite some law enforcement successes, organizations engaged in counterfeiting continued manufacturing, distributing and selling a wide range of unsafe medicines during the past year. This article will identify some of these successes that were made p…